1. Health
Send to a Friend via Email

Study Results Offer Hope for Bronchiectasis Treatment

By January 24, 2009

An inhaled version of the antibiotic ciprofloxacin produced positive results in a Phase II trial studying its use in the treatment of bronchiectasis, a type of lung damage that can occur in people with cystic fibrosis and other lung diseases as a result of frequent lung infections. Earlier this week, Aradigm Corporation reported that single daily doses of inhaled liposomal ciprofloxacin hydrochloride (ILCH) given over a four week period significantly reduced the amount of Pseudomnas aeruginosa in the lungs of the study participants. This particular study of ILCH is being done on people whose bronchietasis is not related to cystic fibrosis, but the drug has been tested in the past on a small group of people with cystic fibrosis. In that study, single daily doses of ILCH produced equally positive results.

Related Articles:

What is Bronchiectasis?
What is Pseudomonas aeruginosa?

Comments are closed for this post.
Leave a Comment

Line and paragraph breaks are automatic. Some HTML allowed: <a href="" title="">, <b>, <i>, <strike>

©2014 About.com. All rights reserved.

We comply with the HONcode standard
for trustworthy health
information: verify here.